GlobeNewswire: Apellis Pharmaceuticals, Inc. Contains the last 10 of 287 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T17:26:21ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/11/2843618/0/en/Apellis-Appoints-Leading-Expert-Dr-Philip-Ferrone-as-Chief-Medical-Retina-Advisor.html?f=22&fvtc=4&fvtv=30610Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor2024-03-11T11:00:00Z<![CDATA[WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief Medical Retina Advisor, effective March 18.]]>https://www.globenewswire.com/news-release/2024/03/06/2841772/0/en/Apellis-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=30610Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2024-03-06T21:05:00Z<![CDATA[WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant date of March 1, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2024/02/27/2835873/0/en/Apellis-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=30610Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results2024-02-27T12:05:00Z<![CDATA[WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its fourth quarter and full year 2023 financial results and business highlights.]]>https://www.globenewswire.com/news-release/2024/02/26/2834993/0/en/Apellis-Pharmaceuticals-to-Present-at-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=30610Apellis Pharmaceuticals to Present at Upcoming Investor Conferences2024-02-26T12:00:00Z<![CDATA[WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following March investor conferences:]]>https://www.globenewswire.com/news-release/2024/02/20/2831652/0/en/Apellis-Pharmaceuticals-to-Host-Conference-Call-on-February-27-2024-to-Discuss-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=30610Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results2024-02-20T12:00:00Z<![CDATA[WALTHAM, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2023 financial results on Tuesday, February 27, 2024, at 8:30 a.m. ET.]]>https://www.globenewswire.com/news-release/2024/02/06/2824714/0/en/Apellis-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=30610Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2024-02-06T21:05:00Z<![CDATA[WALTHAM, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to 4 new employees with a grant date of February 1, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2024/01/26/2817840/0/en/Apellis-Announces-Negative-CHMP-Opinion-for-Pegcetacoplan-for-GA-in-the-European-Union-and-Plans-to-Seek-Re-Examination-of-Application.html?f=22&fvtc=4&fvtv=30610Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application2024-01-26T12:06:23Z<![CDATA[WALTHAM, Mass., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a negative opinion on the marketing authorization application (MAA) of intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As previously announced, this opinion was expected based on a negative trend vote following an oral explanation meeting in December 2023. Apellis plans to seek immediate re-examination of its application.]]>https://www.globenewswire.com/news-release/2024/01/08/2805508/0/en/Apellis-Announces-Preliminary-Fourth-Quarter-and-Full-Year-2023-U-S-Net-Product-Revenues.html?f=22&fvtc=4&fvtv=30610Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues2024-01-08T14:00:00Z<![CDATA[WALTHAM, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced preliminary U.S. net product revenues of approximately $138 million for the fourth quarter and approximately $366 million for the full year 2023 for SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration and for EMPAVELI® (pegcetacoplan) for adults with paroxysmal nocturnal hemoglobinuria (PNH).]]>https://www.globenewswire.com/news-release/2024/01/05/2804869/0/en/Apellis-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=30610Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2024-01-05T21:05:00Z<![CDATA[WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to 2 new employees with a grant date of January 2, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2024/01/02/2802561/0/en/Apellis-Pharmaceuticals-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=30610Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference2024-01-02T12:00:00Z<![CDATA[WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 9:45 a.m. PT.]]>